Skip to main content
. Author manuscript; available in PMC: 2022 Mar 4.
Published in final edited form as: Clin Cancer Res. 2021 Feb 10;27(11):3190–3200. doi: 10.1158/1078-0432.CCR-20-3363

Figure 2. Synergy between FAKi and MEKi in UM and mUM cells.

Figure 2.

(A) Left, 92.1 cell viability 72h after treatment. Right, Combination Index values (CI) determined using the Chou-Talalay method (CI<1 synergism, CI=1 additivity, CI>1 antagonism, scale from −2 to +2). Bottom, ΔBliss scores (score<0 synergism, score=0 additivity, score>0 antagonism, scale from −1 to +1). (B) CI at relevant doses (viability=50±5%) using various combinations of FAKi/MEKi. (C) Immunoblot depicting BAP1 levels in UM and mUM patient-derived cells. (D) Delta score (ΔBliss), assessing synergism between MEKi (trametinib, 10nM) and FAKi (VS-4718, 1μM) in a panel of UM and mUM cells with distinct BAP1 status.